Gemcitabine and Cisplatin Combination Chemotherapy in Triple Negative Metastatic Breast Cancer Previously Treated with a Taxane/Anthracycline Chemotherapy; Multicenter Experience

Basit Öğe Kaydı
dc.contributor.authorOzkan, M.
dc.contributor.authorBerk, V.
dc.contributor.authorKaplan, M. A.
dc.contributor.authorBenekli, M.
dc.contributor.authorCoskun, U.
dc.contributor.authorBilici, A.
dc.contributor.authorGumus, M.
dc.date.accessioned2024-04-24T17:24:18Z
dc.date.available2024-04-24T17:24:18Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractThis study was aimed to establish clinical efficacy and tolerability of gemcitabine and cisplatin combination in patients with metastatic triple negative breast cancer progressing after anthracycline and taxane based chemotherapies. Thirty-three patients who were given cisplatin and gemcitabine for triple negative and metastatic breast cancer were evaluated retrospectively. A total of 141 cycles were administered with a median 4 cycles per patient. Median follow-up time was 14 months (range, 2-36 months). Objective response rate was 27.3%. Total clinical benefit of the combination was 48.4%. The estimated median progression free survival and median overall survival were 5 months and 14 months, respectively. The most common Grade 3 and 4 toxicity were neutropenia and thrombocytopenia observed in 10 (27.7%) and 9 (24.9%) patients, respectively. The combination of the gemcitabine and cisplatin after taxane/anthracycline is well tolerated and seems to be effective with acceptable toxicity profile.en_US
dc.identifier.doi10.4149/neo_2012_005
dc.identifier.endpage42en_US
dc.identifier.issn0028-2685
dc.identifier.issn1338-4317
dc.identifier.issue1en_US
dc.identifier.pmid22103897
dc.identifier.scopus2-s2.0-84863770666
dc.identifier.scopusqualityQ2
dc.identifier.startpage38en_US
dc.identifier.urihttps://doi.org/10.4149/neo_2012_005
dc.identifier.urihttps://hdl.handle.net/11468/19597
dc.identifier.volume59en_US
dc.identifier.wosWOS:000299452800005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAepress Sroen_US
dc.relation.ispartofNeoplasma
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTriple Negativeen_US
dc.subjectMetastatic Breast Canceren_US
dc.subjectCisplatinen_US
dc.subjectGemcitabineen_US
dc.titleGemcitabine and Cisplatin Combination Chemotherapy in Triple Negative Metastatic Breast Cancer Previously Treated with a Taxane/Anthracycline Chemotherapy; Multicenter Experienceen_US
dc.titleGemcitabine and Cisplatin Combination Chemotherapy in Triple Negative Metastatic Breast Cancer Previously Treated with a Taxane/Anthracycline Chemotherapy; Multicenter Experience
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu